Theravance Biopharma (TBPH) Announces Dosing of First Patient in TD-1473 Phase 1b as Ulcerative Colitis Treatment
- Wall St lackluster ahead of Easter break, eyes sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Stocks head into quarter-end on the up; yen on intervention watch
- Dollar gains on euro with Fed's Waller hawkish on rates
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Timken (TKR) Appoints Tarak Mehta as New CEO
Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis
October 4, 2016 8:05 AM EDTDUBLIN, IRELAND -- (Marketwired) -- 10/04/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 1b clinical trial of TD-1473 in patients with moderate to severe ulcerative colitis. TD-1473 is a novel, potent, orally administered and intestinally restricted pan-Janus kinase (JAK) inhibitor in clinical development, with the potential to treat a range of inflammatory intestinal diseases. Importantly, TD-1473 is specifically designed to act directly at the site of inflammation in the intestinal wall with minimal systemic exposure.
The Phase 1b trial is a multi-center, randomized,... More